Resources from the same session
LBA4 - Osimertinib (osi) after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable (UR) stage III EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC): Updated overall survival (OS) analysis from the LAURA study
Presenter: Suresh Ramalingam
Session: Proffered Paper session 2
Resources:
Abstract
Slides
Webcast
186O - Pembrolizumab (pembro) plus concurrent chemoradiation therapy (cCRT) in unresectable locally advanced non-small cell lung cancer (NSCLC): Final analysis of KEYNOTE-799
Presenter: Martin Reck
Session: Proffered Paper session 2
Resources:
Abstract
Slides
Webcast
Invited discussant LBA4 and 186O
Presenter: Sara Ramella
Session: Proffered Paper session 2
Resources:
Slides
Webcast
Q&A and discussion
Session: Proffered Paper session 2
Resources:
Webcast
187O - A multifactorial score to predict surgical complexity of lung resection following neoadjuvant chemo-immunotherapy
Presenter: Marco Nardini
Session: Proffered Paper session 2
Resources:
Abstract
Slides
Webcast
LBA3 - Sites of relapse and subsequent therapy in the BR.31 phase III study of durvalumab vs placebo in resected stage IB-IIIA NSCLC
Presenter: Virginie Westeel
Session: Proffered Paper session 2
Resources:
Abstract
Slides
Webcast
188O - Patient-reported outcomes (PROs) with perioperative durvalumab in resectable NSCLC (AEGEAN)
Presenter: Giulia Pasello
Session: Proffered Paper session 2
Resources:
Abstract
Slides
Webcast
Q&A and discussion
Session: Proffered Paper session 2
Resources:
Webcast